(redirected from Aerospan)
Also found in: Dictionary.


a steroid antiinflammatory agent administered as an aerosol spray for treatment of bronchial asthma and seasonal or perennial allergic rhinitis when conventional treatment is unsatisfactory.


APO-Flunisolide (CA), Nasarel, PMS-Flunisolide (CA), Ratio-Flunisolide (CA), Rhinalar Nasal Mist (CA)

Pharmacologic class: Intranasal steroid

Therapeutic class: Respiratory inhalant

Pregnancy risk category C


Unknown. Thought to diminish capillary permeability and suppress migration of polymorphonuclear leukocytes, decreasing inflammation.


Spray solution: 25 ml (each actuation delivers approximately 25 mcg)

Indications and dosages

Relief of seasonal or perennial rhinitis

Adults: Two sprays in each nostril b.i.d.; may increase to two sprays in each nostril t.i.d. Maximum daily dose is eight sprays in each nostril. For maintenance, after desired clinical effect occurs, reduce dosage to smallest amount needed to control symptoms.

Children ages 6 to 14: One spray in each nostril t.i.d. or two sprays in each nostril b.i.d.; maximum daily dose is four sprays in each nostril. For maintenance, after desired clinical effect occurs, reduce dosage to smallest amount needed to control symptoms.


• Hypersensitivity to drug or its components
• Untreated local infections of nasal mucosa


Use cautiously in:
• localized Candida albicans infection; tuberculosis; untreated fungal, bacterial, or systemic viral infections; ocular herpes simplex
• patients receiving immunosuppressive therapy.


• Don't increase dosage or discontinue drug abruptly.

Adverse reactions

CNS: headache, light-headedness, nervousness, dizziness

EENT: cataracts; glaucoma; blurred vision; conjunctivitis; increased intraocular pressure; lacrimation; dry, irritated eyes; tinnitus; otitis; otitis media; rhinorrhea; rhinitis; nasal irritation, burning, and dryness; nasal stuffiness and pain; sneezing; nasal ulcer; epistaxis; localized Candida albicans nasal infections; nasal mucosa ulcerations; nasal septum perforation; throat discomfort, soreness, and dryness; mild nasopharyngeal irritation; pharyngitis; dry mucous membranes; nasal and sinus congestion; sinusitis; hoarseness, voice changes

GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia, dry mouth

Metabolic: hyperadrenocorticism

Musculoskeletal: myalgia, arthralgia, aseptic necrosis of femoral head

Respiratory: wheezing, dyspnea, increased cough, bronchitis, bronchospasm, asthma symptoms

Skin: rash, pruritus, urticaria, contact dermatitis, alopecia, herpes simplex infection

Other: altered taste and smell, facial edema, fever, flulike symptoms, aches and pains, infections, angioedema, anaphylaxis


Drug-diagnostic tests.Aspartate aminotransferase: increased level

Patient monitoring

Monitor patient closely for serious adverse reactions, including anaphylaxis, angioedema, hyperadrenocorticism, and serious infections.

Patient teaching

Teach patient to recognize and immediately report serious adverse reactions.
• Teach patient proper use of drug. Caution him not to use more than prescribed amount; doing so may cause serious side effects.
• Tell patient maximum drug effects may not occur for several weeks.
• Tell patient to avoid people with measles, chickenpox, and other transmissible infections.
• Caution patient to withhold dose and contact prescriber if infection occurs.
• Instruct female patient to tell prescriber if she becomes pregnant.
• Tell female patient not to breastfeed without consulting prescriber.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


/flu·nis·o·lide/ (floo-nis´o-līd″) a synthetic glucocorticoid used as the acetate salt in treatment of bronchial asthma and seasonal and nonseasonal allergic rhinitis.


A corticosteroid, C24H31FO6, administered by inhalation to treat asthma and nasally to treat allergies.


an intranasal and oral inhalation adrenal corticosteroid.
indications It is prescribed in the treatment of seasonal or continuing allergic rhinitis that involves inflammation of the mucous membranes of the nasal passages and for the treatment of asthma.
contraindications It should not be given to patients with allergy to this drug or any of its components or to patients with status asthmaticus or untreated bacterial, viral, or fungal infections of the respiratory tract or nasal mucosa.
adverse effects The side effects most often reported include nasal or throat irritation, stinging, burning, or dryness; nosebleed; sneezing; bloody mucus; congestion; asthma; increased coughing; sore throat; or lesions in the nose or throat.


Aerobid® An inhalant corticosteroid used to manage asthma


A CORTICOSTEROID drug used in the form of a spray to treat hay fever. A brand name is Syntaris.


n brand name: Oral INH aerosol, AeroBid;
drug class: synthetic glucocorticoid;
action: long-acting synthetic adrenocorticoid with antiinflammatory activity;
use: rhinitis (seasonal or perennial).
References in periodicals archive ?
Aerospan is an inhaler for the treatment of asthma that contains the active substance Flunisolide and is approved by the FDA.
Acton, a privately held company, acquired the rights to Aerospan under a license from Forest Laboratories Inc.
The therapeutic indications of NASACORT HFA and AEROSPAN are complementary and will enable us to provide a highly targeted commercial effort directed toward respiratory and pediatric physicians," stated John Simon of Acton Pharmaceuticals.
Through this transaction Aerospan will now be commercialized by a company with one of the leading respiratory-focused sales forces in the U.
Treatment with orally inhaled corticosteroids including AEROSPAN, may lead to signs or symptoms of hypercorticism, suppression of hypothalamic-pituitary -adrenal (HPA) function and/or suppression of growth in children.
Food and Drug Administration (FDA), a Manufacturing Supplement to the previously approved AEROSPAN Inhalation Aerosol NDA.
pharmaceutical company, gives Acton exclusive rights to develop and market AEROSPAN in the $7.
We are very pleased to license AEROSPAN from Forest and to complete this round of financing with Sequoia Capital," stated John W.
We are also anticipating that the approval of Aerospan for asthma may occur this year and that the approval of memantine for the treatment of moderate to severe Alzheimer's may occur early next fiscal year.
He has also served as Senior Vice President, Marketing and Business Development for Aerospan and Senior Director, Aerospace and Defense Solutions for Oracle Corporation respectively.

Full browser ?